These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Empagliflozin attenuates neointimal hyperplasia after drug-eluting-stent implantation in patients with type 2 diabetes. Hashikata T; Ikutomi M; Jimba T; Shindo A; Kakuda N; Katsushika S; Yokoyama M; Kishi M; Sato T; Matsushita M; Ohnishi S; Yamasaki M Heart Vessels; 2020 Oct; 35(10):1378-1389. PubMed ID: 32399662 [TBL] [Abstract][Full Text] [Related]
24. Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial. Nesti L; Pugliese NR; Sciuto P; Trico D; Dardano A; Baldi S; Pinnola S; Fabiani I; Di Bello V; Natali A Cardiovasc Diabetol; 2022 Sep; 21(1):181. PubMed ID: 36096863 [TBL] [Abstract][Full Text] [Related]
25. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K; Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850 [TBL] [Abstract][Full Text] [Related]
27. Impact of Empagliflozin on Left Ventricular Strain: Insights From the EMPA-HEART CardioLink-6 Randomized Clinical Trial. Moses S; Verma S; Mazer CD; Teoh H; Quan A; Jimenez-Juan L; Deva DP; Yan AT; Connelly KA JACC Cardiovasc Imaging; 2022 Oct; 15(10):1832-1834. PubMed ID: 36202464 [No Abstract] [Full Text] [Related]
28. Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus: The IDDIA Trial. Shim CY; Seo J; Cho I; Lee CJ; Cho IJ; Lhagvasuren P; Kang SM; Ha JW; Han G; Jang Y; Hong GR Circulation; 2021 Feb; 143(5):510-512. PubMed ID: 33186508 [No Abstract] [Full Text] [Related]
29. [Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME]. Scheen AJ Rev Med Liege; 2019 Apr; 74(4):185-191. PubMed ID: 30997967 [TBL] [Abstract][Full Text] [Related]
30. Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: a cardiac magnetic resonance study. Cohen ND; Gutman SJ; Briganti EM; Taylor AJ Intern Med J; 2019 Aug; 49(8):1006-1010. PubMed ID: 30784160 [TBL] [Abstract][Full Text] [Related]
31. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. Santos-Gallego CG; Requena-Ibanez JA; San Antonio R; Ishikawa K; Watanabe S; Picatoste B; Flores E; Garcia-Ropero A; Sanz J; Hajjar RJ; Fuster V; Badimon JJ J Am Coll Cardiol; 2019 Apr; 73(15):1931-1944. PubMed ID: 30999996 [TBL] [Abstract][Full Text] [Related]
33. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Shimizu W; Kubota Y; Hoshika Y; Mozawa K; Tara S; Tokita Y; Yodogawa K; Iwasaki YK; Yamamoto T; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Ishikawa M; Maruyama M; Ogano M; Tanabe J; Cardiovasc Diabetol; 2020 Sep; 19(1):148. PubMed ID: 32977831 [TBL] [Abstract][Full Text] [Related]
34. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B; Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068 [TBL] [Abstract][Full Text] [Related]
35. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Fitchett D; Inzucchi SE; Cannon CP; McGuire DK; Scirica BM; Johansen OE; Sambevski S; Kaspers S; Pfarr E; George JT; Zinman B Circulation; 2019 Mar; 139(11):1384-1395. PubMed ID: 30586757 [TBL] [Abstract][Full Text] [Related]
36. [EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk]. Scheen AJ Rev Med Liege; 2015 Nov; 70(11):583-9. PubMed ID: 26738271 [TBL] [Abstract][Full Text] [Related]
37. Impact of empagliflozin in patients with diabetes and heart failure. Pham D; Albuquerque Rocha N; McGuire DK; Neeland IJ Trends Cardiovasc Med; 2017 Feb; 27(2):144-151. PubMed ID: 27612553 [TBL] [Abstract][Full Text] [Related]
38. Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension. Chilton R; Tikkanen I; Hehnke U; Woerle HJ; Johansen OE Diabetes Obes Metab; 2017 Nov; 19(11):1620-1624. PubMed ID: 28387058 [TBL] [Abstract][Full Text] [Related]
39. Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus. Hsu JC; Wang CY; Su MM; Lin LY; Yang WS Sci Rep; 2019 Oct; 9(1):15348. PubMed ID: 31653956 [TBL] [Abstract][Full Text] [Related]
40. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure. Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]